The MI 2 MALT1 inhibitor is primarily used in research and therapeutic contexts to target and modulate the activity of the MALT1 protease, which plays a critical role in immune signaling pathways, particularly in the NF-κB pathway. By inhibiting MALT1, this compound helps in studying the mechanisms of immune cell activation and proliferation, making it valuable in understanding diseases like lymphomas and autoimmune disorders. It is also explored for its potential in developing treatments for B-cell malignancies, as MALT1 inhibition can suppress the survival and growth of cancerous cells. Additionally, it serves as a tool in preclinical studies to evaluate the efficacy of targeting MALT1 in various inflammatory and oncological conditions.